期刊文献+

度他雄胺治疗良性前列腺增生症的临床研究进展 被引量:4

Research progress of dutasteride in men with benign prostatic hyperplasia
原文传递
导出
摘要 度他雄胺是一种良好的治疗良性前列腺增生的药物,由于其疗效肯定、不良反应少等优点而备受关注。本文从度他雄胺抑制血清双氢睾酮水平、缩小前列腺体积、改善最大尿流率、降低IPSS评分、改善生活质量、降低急性尿潴留发生率、降低血前列腺特异抗原水平等方面的疗效及其存在的不良反应的方面介绍该药的研究进展,为该药的进一步研究及临床应用提供参考依据。 Dutasteride is a good medicine in treating benign prostatic hyperplasia (BPH) . Because of positive clinical efficacy and less adverse reaction, it is getting obtained more and more attention. The efficacy and safety of dutasteride on suppression of serum DHT levels, reducing the prostate volume, improving themaximum flow rate, decreasing the IPSS score, improving quality of life, reducing the incidence of acute urinary retention, decreasing the serum PSA level and related adverse reactions are reviewed in this paper in order to provide reference frames for its further research and clinical application.
作者 穆鑫 薛蔚
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第2期97-100,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 良性前列腺增生症 度他雄胺 临床研究 治疗 IPSS评分 不良反应 前列腺体积 最大尿流率 prostatic hyperplasia drug therapy dutasteride 5ot-reductase inhibitor
  • 相关文献

参考文献16

  • 1XU Y, DALRYMPLE SL, BECKER RE, et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers[J]. Clin Cancer Res, 2006, 12(13): 4072-4079. 被引量:1
  • 2CLARK RV, HERMANN DJ, CUNNINGHAM GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5- alpha- reductase inhibitor [J]. J Clin Endocrinol Metab 2004, 89(5): 2179-2184. 被引量:1
  • 3ROEHRBORN CG, BOYLE P, NICKEL JC, et al. Efficacy and safety of a dual inhibitor of 5- alpha- reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia[J]. Urology 2002, 60(3): 434-441. 被引量:1
  • 4DEBRUYNE F, BARKIN J, van ERPS P, et ol. Efficacy and safety of long- term treatment with the dual 5- alpha- reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia[J]. Eur Urol, 2004, 46(4) : 488-494. 被引量:1
  • 5CHOI YH, CHO SY, CHO IR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride[J]. Korean J Urol, 2010, 51(10): 704-708. 被引量:1
  • 6O'LEARY MP, ROEHRBORN CG, BLACK L. Dutastefide significantly improves quality of life measures in patients with enlarged prostate[J]. Prostate Cancer Prostatic Dis, 2008, 11 (2) : 129-133. 被引量:1
  • 7ISSA MM, RUNKEN MC, GROGG AL, et al. A large retrospective analysis of acute urinary retention and prostate- related surgery in BPH patients treated with 5- alpha-reductase inhibitors: dutasteride versus finasteride[J]. Am J Manag Care, 2007, 13 Suppl 1: 10-16. 被引量:1
  • 8FENTER TC, DAVIS EA, SHAH MB, et ol. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or = 65 years[J]. Am J Manag Care, 2008, 14(5 Suppl 2) : S154- S159. 被引量:1
  • 9ANDRIOLE GL, MARBERGER M, ROEHRBORN CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5-alpha- reductase inhibitor dutasteride[J]. J Urol, 2006, 175(5): 1657- 1662. 被引量:1
  • 10AMORY JK, ANAWALT BD, MATSUMOTO AM, et ol. The effect of 5-alpha-reductase inhibition with dutasteride and finaste- ride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men[J]. J Urol, 2008, 179(6) : 2333-2338. 被引量:1

同被引文献34

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2谢立平,白宇.良性前列腺增生症下尿路症状的治疗进展[J].中华老年医学杂志,2006,25(11):873-875. 被引量:4
  • 3郭应禄,周利群.坎贝尔.沃尔什泌尿外科学[M].北京:北京大学医学出版社,2009:741-774. 被引量:2
  • 4CLARK RV, HERMANN DJ, CUNNINGHAM GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatichyperplasia by dutasteride, A dual 5 alpha-reductase inhibitor[J]. Clin Endocrinol Metab, 2004, 89(5): 2179-2184. 被引量:1
  • 5CHOI YH, CHO SY, CHOIR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride[J]. Korean J Urol, 2010, 51(10): 704-708. 被引量:1
  • 6TSUKAMOTO T, ENDO Y, NARITA M. Assessment of recom- mended dose of dutasteride on Jananese man with benign pro- static hyperplasia A randomized double-blind placebo-controlled paralled-group dose response study[J]. Hinyokika Kiyo, 2009, 55 (4): 209-214. 被引量:1
  • 7ROEHRBOM CG, SIAMI P, BARKIN J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the Comb AT study[J]. Eur Urol, 2010, 57 (1): 123-131. 被引量:1
  • 8BARKIN J, ROEHRBOM CG, SIAMI P, et al. Effect of dutas- teride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the comb AT trial[J]. BJU Int, 2009, 103(7): 919-926. 被引量:1
  • 9ANDRIOLE GL, BOSTWICK DG, BRAWLEY OW, et al. Effect of dutasteride on the risk of prostate cancer[J]. The New England Journal of Medicine, 2010, 362(13): 1192-1202. 被引量:1
  • 10SCHULMAN C, POMMERVILLE P, HLFNER K, et al. Long-term therapy with the dual 5 alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia[J]. BJU Int, 2006, 97(1): 73-79. 被引量:1

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部